Coordinating Your Care and Management
At a Glance
Because autosomal dominant striatal degeneration has no established cure or standard treatment protocol, care is individualized. A movement-disorder team can use levodopa trials, physical and occupational therapy, swallowing assessments, and safety planning to preserve mobility and quality of life.
Because Autosomal Dominant Striatal Degeneration (ADSD) is so rare, there is no “standard” treatment protocol or cure. Instead, care is symptom-focused and highly individualized [1][2]. The goal is not just to treat the disease on paper, but to help you move more easily, stay safe in your home, and maintain your quality of life over the long term.
Your Care Team: The Multidisciplinary Approach
Managing a complex condition like ADSD requires a “team of experts” rather than a single doctor. Because the condition affects the striatum, your primary guide should be a Movement Disorder Specialist—a neurologist with advanced training in the basal ganglia [3].
Your team will likely include several other specialists:
- Neurogenetics: To confirm the PDE8B mutation and provide counseling for your family [4].
- Physical Therapy (PT): Focused on improving your walking (gait), balance, and overall physical conditioning [5].
- Occupational Therapy (OT): Focused on making daily tasks (like dressing or cooking) easier and ensuring your home environment is safe [6].
- Speech-Language Pathology (SLP): To monitor your voice and, critically, your ability to swallow safely [7].
The Levodopa Trial
In many conditions that cause parkinsonism, doctors will recommend a trial of levodopa (often as Sinemet). Levodopa helps the brain by providing the raw material for dopamine, which the striatum uses to coordinate movement [8].
In ADSD, the response to levodopa is variable and unpredictable [9].
- It may help: Some people with genetic parkinsonism experience a meaningful improvement in stiffness and slowness [10]. Evidence for levodopa responsiveness in this ultra-rare condition is limited.
- It may not: Because ADSD involves the “downstream” part of the brain (the striatum) rather than just a lack of dopamine, the medication might have a limited effect [11][12].
- Objective Testing: It is important to have an “objective” trial. This means your specialist may choose an individualized therapeutic trial examining your movement before you take the medication and after it has kicked in, using a standardized scale like the UPDRS to see if there is a measurable change [11][13]. A lack of response to levodopa does not mean your diagnosis is wrong, nor does a response confirm it; it is simply a common feature to test for this specific disease [12]. Be aware of relevant adverse effects such as nausea, orthostatic hypotension, hallucinations, and dyskinesias; patients should not stop levodopa abruptly.
Proactive Therapy and Monitoring
Rather than waiting for significant disability, a “proactive” model of care is recommended. This means starting therapy early to build a “buffer” of strength and safety.
- Mobility and Falls: A physical therapist can teach you specific techniques to manage bradykinesia (slowness) and balance issues. They can also assess your gait and fit the least restrictive appropriate aid, such as a cane or rollator when indicated, and teach safe use [14].
- Swallowing and Nutrition: One of the most important aspects of long-term care is monitoring for dysphagia (swallowing difficulty). An SLP can perform a clinical swallowing evaluation, and if symptoms warrant, an instrumental study like a videofluoroscopy to ensure food and liquid are not entering your lungs (aspiration), which can cause pneumonia [15][16].
- Energy Conservation: An occupational therapist can evaluate your home for “trip hazards” and suggest tools (like button hooks or ergonomic kitchenware) that reduce the physical effort required for daily living [6].
Because ADSD is slowly progressive, your needs will change over time. Regular follow-ups—even when you feel “stable”—allow your team to adjust your care plan and catch small issues before they become major hurdles. Care should be adapted to the person’s actual symptoms and goals, including nonmotor issues such as mood, cognition, sleep, fatigue, pain, and autonomic symptoms.
Common questions in this guide
Is there a standard treatment or cure for ADSD?
Can levodopa help people with ADSD?
Which specialists should be part of an ADSD care team?
Should I have a swallowing evaluation if I have not noticed choking?
How can physical and occupational therapy help with ADSD?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Can we conduct a structured 'OFF/ON' levodopa trial with an objective motor scale (like the UPDRS) to see if it truly helps my mobility?
- 2.Since there are no specific guidelines for ADSD, how can we adapt protocols from other atypical parkinsonisms to monitor my swallowing and gait?
- 3.Which movement disorder specialists or neurogenetics centers in our region have experience with ultra-rare striatal conditions?
- 4.What specific parameters should my physical therapist focus on to address both the parkinsonism and the ataxia components of my condition?
- 5.Should I have a clinical swallowing evaluation to determine if I need a baseline swallow study even if I haven't noticed significant choking yet?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.
Saffie Awad P, Teixeira-Dos-Santos D, Santos-Lobato BL, et al.
Movement disorders : official journal of the Movement Disorder Society 2024; (39(1)):6-16 doi:10.1002/mds.29614.
PMID: 37921246 - 2
Expanding the Genotypic Spectrum of SLC18A2 Mutation-Related Disorder-A Novel Mutation and Review of Literature.
Brewer S, Ramani PK, Arya K
Journal of child neurology 2026; (41(9)):1358-1364 doi:10.1177/08830738261416724.
PMID: 41804711 - 3
The Genetic Landscape of Complex Childhood-Onset Hyperkinetic Movement Disorders.
Pérez-Dueñas B, Gorman K, Marcé-Grau A, et al.
Movement disorders : official journal of the Movement Disorder Society 2022; (37(11)):2197-2209 doi:10.1002/mds.29182.
PMID: 36054588 - 4
French guidelines for the diagnosis and management of pure hereditary spastic paraplegia.
Mania-Pâris L, Ewenczyk C, Nicolas G, et al.
Revue neurologique 2025; (181(6)):471-482 doi:10.1016/j.neurol.2025.05.001.
PMID: 40450402 - 5
Rehabilitation Interventions in Adults with Amyotrophic Lateral Sclerosis: A Review :.
Behroozinia M, Khosrawi S
Galen medical journal 2025; (14()):e3708 doi:10.31661/gmj.vi.3708.
PMID: 42038869 - 6
Huntington's Disease: A Report of an Interesting Case and Literature Review.
Sharma PK, Aram A, Polaka Y, Pandian V
Cureus 2024; (16(3)):e55443 doi:10.7759/cureus.55443.
PMID: 38567236 - 7
Multi-Modal Rehabilitation Therapy in Parkinson's Disease and Related Disorders.
Saluja A, Goyal V, Dhamija RK
Annals of Indian Academy of Neurology 2023; (26(Suppl 1)):S15-S25 doi:10.4103/aian.aian_164_22.
PMID: 37092020 - 8
Therapeutic drug monitoring in Parkinson's disease.
Müller T, Gerlach M, Hefner G, et al.
Journal of neural transmission (Vienna, Austria : 1996) 2024; (131(10)):1247-1262 doi:10.1007/s00702-024-02828-5.
PMID: 39227478 - 9
Levodopa-carbidopa intestinal gel for multiple system atrophy with motor fluctuations: a case series.
Iseki T, Nishikawa N, Ogawa T, et al.
Therapeutic advances in neurological disorders 2025; (18()):17562864251360048 doi:10.1177/17562864251360048.
PMID: 40786524 - 10
Long-term efficacy of bilateral subthalamic deep brain stimulation in the parkinsonism of SCA 3: A rare case report.
Kuo MC, Tai CH, Tseng SH, Wu RM
European journal of neurology 2022; (29(8)):2544-2547 doi:10.1111/ene.15339.
PMID: 35837753 - 11
Do patients with late-stage Parkinson's disease still respond to levodopa?
Fabbri M, Coelho M, Abreu D, et al.
Parkinsonism & related disorders 2016; (26()):10-6.
PMID: 26972527 - 12
Clinical findings of autosomal-dominant striatal degeneration and PDE8B mutation screening in parkinsonism and related disorders.
Ni J, Yi X, Liu Z, et al.
Parkinsonism & related disorders 2019; (69()):94-98 doi:10.1016/j.parkreldis.2019.11.002.
PMID: 31726290 - 13
Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?
Pintér D, Forjaz MJ, Martinez-Martin P, et al.
Journal of Parkinson's disease 2020; (10(1)):275-282 doi:10.3233/JPD-191800.
PMID: 31868685 - 14
Gait, balance, and falls in Huntington disease.
Vuong K, Canning CG, Menant JC, Loy CT
Handbook of clinical neurology 2018; (159()):251-260 doi:10.1016/B978-0-444-63916-5.00016-1.
PMID: 30482318 - 15
Combined use of a double-lumen tube and Fogarty catheter to prevent the endobronchial spread of infection: a case report.
Kim J, Lee H, Park H, Jeong CY
Korean journal of anesthesiology 2016; (69(6)):619-622 doi:10.4097/kjae.2016.69.6.619.
PMID: 27924204 - 16
Enteral Nutrition in Idiopathic Parkinson's Disease and Atypical Parkinsonism: A Systematic Review.
Lonergan B, Ciocca M, Schrag A, Tai Y
Movement disorders clinical practice 2026; doi:10.1002/mdc3.70653.
PMID: 42063328
This page explains symptom-focused care for ADSD for educational purposes and is not medical advice. Discuss levodopa trials, swallowing evaluations, therapy, and safety planning with your movement-disorder specialist.
Get notified when new evidence is published on Autosomal dominant striatal neurodegeneration.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.